N/A
Completed N=30
Mechanism of Action of Ocrelizumab in Multiple Sclerosis
Multiple Sclerosis · Immune System Diseases
Source: ClinicalTrials.gov NCT03344094 ↗
Enrolled (actual)
30
Serious AEs
0.0%
Results posted
Feb 2025
Primary outcomePrimary: Number of Participants With Complete Depletion of B Cells — 15; 0; 0; 0 Participants — p=0.05
Summary
Ocrelizumab is FDA approved for therapy of multiple sclerosis (MS). It depletes B cells and stops MS inflammation.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Complete Depletion of B Cells |
15; 0; 0; 0 | 0.05 |
Eligibility Criteria
Inclusion Criteria
- All patients who are eligible for Ocrelizumab therapy based on FDA criteria
Exclusion Criteria
- All patients who are ineligible for Ocrelizumab therapy based on FDA criteria.
- Prior treatment with Alemtuzumab or stem cell therapy, or immune abnormalities that would interfere with planned tests.
- Hepatitis B and HIV infections.
- Pregnant or lactating women.
- Hypersensitivity to trial medications.
Data sourced from ClinicalTrials.gov (NCT03344094). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.